Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nasdaq  >  Atossa Therapeutics, Inc.    ATOS

ATOSSA THERAPEUTICS, INC.

(ATOS)
  Report
 SummaryQuotesChartsNewsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
02/14/2020 02/18/2020 02/19/2020 02/20/2020 02/21/2020 Date
1.38(c) 1.37(c) 1.36(c) 1.4(c) 1.39 Last
132 546 38 028 45 183 58 033 15 040 Volume
-1.25% -0.72% -0.73% +2.94% -0.71% Change
More quotes
Financials (USD)
Sales 2019 -
EBIT 2019 -18,3 M
Net income 2019 -18,3 M
Debt 2019 -
Yield 2019 -
Sales 2020 -
EBIT 2020 -19,0 M
Net income 2020 -19,0 M
Debt 2020 -
Yield 2020 -
P/E ratio 2019 -0,69x
P/E ratio 2020 -0,93x
Capi. / Sales2019 -
Capi. / Sales2020 -
Capitalization 12,8 M
More Financials
Company
Atossa Therapeutics Inc., formerly Atossa Genetics Inc., is a clinical-stage biopharmaceutical company. The Company is focused on developing therapeutics and delivery methods for breast cancer and other breast conditions. Its pipeline includes two programs: endoxifen and intraductal microcatheter... 
More about the company
Latest news on ATOSSA THERAPEUTICS, INC.
02/10ATOSSA THERAPEUTICS, INC. : Entry into a Material Definitive Agreement, Financia..
AQ
02/05Atossa Therapeutics, Inc. to Present at the 22nd Annual BIO CEO & Investor Co..
GL
02/05ATOSSA THERAPEUTICS : Interview with Atossa Therapeutics' Kyle Guse On World Can..
AQ
01/22Atossa Therapeutics President and CEO Dr. Steven C. Quay Issues Annual Letter..
GL
01/07ATOSSA THERAPEUTICS, INC. : Amendments to Articles of Inc. or Bylaws; Change in ..
AQ
01/06Atossa Genetics Announces Corporate Name Change to Atossa Therapeutics, Inc.
GL
2019ATOSSA GENETICS : Announces Phase 2 Study Contract for Oral Endoxifen to Reduce ..
AQ
2019Atossa Genetics Announces Phase 2 Study Contract for Oral Endoxifen to Reduce..
GL
2019ATOSSA GENETICS : to Present at the LD Micro 12th Annual Main Event on December ..
AQ
2019Atossa Genetics to Present at the LD Micro 12th Annual Main Event on Decembe..
GL
2019ATOSSA GENETICS INC : Results of Operations and Financial Condition, Financial S..
AQ
2019ATOSSA GENETICS : MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AN..
AQ
2019Atossa Genetics Announces Third Quarter 2019 Financial Results and Provides C..
GL
2019ATOSSA GENETICS : to Present on October 29th at the 5th Annual Dawson James Smal..
PU
2019Atossa Genetics to Present on October 29th at the 5th Annual Dawson James Sma..
GL
More news
News in other languages on ATOSSA THERAPEUTICS, INC.
02/04BpiFrance confirme son intention de devenir un actionnaire de référence de Wo..
2019L'Europe dans le désordre avant la Fed, LVMH brille
More news
Sector news : Biotechnology & Medical Research - NEC
02/20Anglo American Discloses All Mine Deaths in Industry Shift--Update
DJ
02/20Anglo American Discloses All Mine Deaths in Industry Shift -- Update
DJ
02/20Anglo American Discloses All Mine Deaths in Industry Shift
DJ
02/20GlaxoSmithKline Invests $50 Million in Biotech Startup's Cell-Therapy Program
DJ
02/19Five Prime Therapeutics In License Agreement with Seattle Genetics
DJ
More sector news : Biotechnology & Medical Research - NEC
Chart ATOSSA THERAPEUTICS, INC.
Duration : Period :
Atossa Therapeutics, Inc. Technical Analysis Chart | ATOS | US04962H5063 | MarketScreener
Technical analysis trends ATOSSA THERAPEUTICS, INC.
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 1
Average target price 4,00  $
Last Close Price 1,40  $
Spread / Highest target 186%
Spread / Average Target 186%
Spread / Lowest Target 186%
EPS Revisions
Managers
NameTitle
Steven C. Quay Chairman, President & Chief Executive Officer
Kyle Guse CFO, Secretary & Chief Accounting Officer
Shu Chih Chen Director
Stephen J. Galli Independent Director
H. Lawrence Remmel Independent Director
Sector and Competitors
1st jan.Capitalization (M$)
ATOSSA THERAPEUTICS, INC.-10.83%13
LONZA GROUP19.03%31 732
IQVIA HOLDINGS INC.6.23%31 649
SEATTLE GENETICS, INC.3.56%20 383
CELLTRION, INC.--.--%19 812
INCYTE CORPORATION-5.61%17 943